Cargando…
123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062941/ https://www.ncbi.nlm.nih.gov/pubmed/9662242 |
_version_ | 1782137234299813888 |
---|---|
author | Raderer, M. Kurtaran, A. Hejna, M. Vorbeck, F. Angelberger, P. Scheithauer, W. Virgolini, I. |
author_facet | Raderer, M. Kurtaran, A. Hejna, M. Vorbeck, F. Angelberger, P. Scheithauer, W. Virgolini, I. |
author_sort | Raderer, M. |
collection | PubMed |
description | Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed promising potential for visualization of various gastrointestinal adenocarcinomas by means of [123I]VIP. In this article, we now report the results obtained in 80 consecutive patients with colorectal adenocarcinoma. Eighty consecutive patients with histologically verified colorectal cancer underwent scanning by means of [123I]VIP (1 microg, approximately 150 MBq). Thirteen patients were free of tumour after complete resection of Dukes' C cancer, eight patients presented with primary and 14 with locally recurrent tumours but were free of metastases. Ten patients had locally recurrent disease and liver, lung or lymph node metastases. Disease confined to organ metastases (i.e. liver, lung or lymph nodes) was present in 35 patients. The size of the primary or recurrent tumours ranged between 3 and 6 cm, and the size of metastases was between 1 and 13 cm in diameter. Scan results were evaluated independently by two nuclear medicine physicians in a blinded way, and results were then compared with computerized tomography (CT)scans not older than 4 weeks. Seven out of eight primary (87%) and 21 out of 24 (82%) locally relapsing cancers were imaged with [123I]VIP. Negative VIP scans were obtained in all 13 patients in whom the cancers had been curatively resected. All patients with lymph node metastases showed positive VIP scans (four out of four), and positive scans were obtained in 25 out of 28 (89%) patients with liver metastases and in two out of three cases with lung metastases. In four patients with relapsing cancer, the VIP scan indicated the presence of disease before CT, and in two patients the diagnosis of scar tissue instead of a local recurrence of rectal cancer as suggested by CT could be established. We conclude that [123I]VIP receptor scanning is a sensitive method for radioimaging of colorectal cancer with the potential to provide valuable additional information to conventional radiological methods. IMAGES: |
format | Text |
id | pubmed-2062941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | Nature Publishing Group|1 |
record_format | MEDLINE/PubMed |
spelling | pubmed-20629412009-09-10 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Raderer, M. Kurtaran, A. Hejna, M. Vorbeck, F. Angelberger, P. Scheithauer, W. Virgolini, I. Br J Cancer Research Article Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed promising potential for visualization of various gastrointestinal adenocarcinomas by means of [123I]VIP. In this article, we now report the results obtained in 80 consecutive patients with colorectal adenocarcinoma. Eighty consecutive patients with histologically verified colorectal cancer underwent scanning by means of [123I]VIP (1 microg, approximately 150 MBq). Thirteen patients were free of tumour after complete resection of Dukes' C cancer, eight patients presented with primary and 14 with locally recurrent tumours but were free of metastases. Ten patients had locally recurrent disease and liver, lung or lymph node metastases. Disease confined to organ metastases (i.e. liver, lung or lymph nodes) was present in 35 patients. The size of the primary or recurrent tumours ranged between 3 and 6 cm, and the size of metastases was between 1 and 13 cm in diameter. Scan results were evaluated independently by two nuclear medicine physicians in a blinded way, and results were then compared with computerized tomography (CT)scans not older than 4 weeks. Seven out of eight primary (87%) and 21 out of 24 (82%) locally relapsing cancers were imaged with [123I]VIP. Negative VIP scans were obtained in all 13 patients in whom the cancers had been curatively resected. All patients with lymph node metastases showed positive VIP scans (four out of four), and positive scans were obtained in 25 out of 28 (89%) patients with liver metastases and in two out of three cases with lung metastases. In four patients with relapsing cancer, the VIP scan indicated the presence of disease before CT, and in two patients the diagnosis of scar tissue instead of a local recurrence of rectal cancer as suggested by CT could be established. We conclude that [123I]VIP receptor scanning is a sensitive method for radioimaging of colorectal cancer with the potential to provide valuable additional information to conventional radiological methods. IMAGES: Nature Publishing Group|1 1998-07 /pmc/articles/PMC2062941/ /pubmed/9662242 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Raderer, M. Kurtaran, A. Hejna, M. Vorbeck, F. Angelberger, P. Scheithauer, W. Virgolini, I. 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. |
title | 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. |
title_full | 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. |
title_fullStr | 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. |
title_full_unstemmed | 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. |
title_short | 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. |
title_sort | 123i-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062941/ https://www.ncbi.nlm.nih.gov/pubmed/9662242 |
work_keys_str_mv | AT radererm 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer AT kurtarana 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer AT hejnam 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer AT vorbeckf 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer AT angelbergerp 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer AT scheithauerw 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer AT virgolinii 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer |